A Phase 3 Randomized, Placebo-controlled Doubleblind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer

Title: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Protocol 56021927PCR3001

EudraCT:                2014-001718-25

Populatie: gemetastaseerd (positieve botscan of adenopathieën op CT).  ECOG 0-1 , minimale pijnmedicatie, uitbehandeld (casodex reeds gestart en gestopt) 3 psa stijgingen.
Patiënt start met Abiraterone + prednisone en dubbelblind androgeen receptor JNJ-56021927

​Contactpersoon:

Els Goossens
Head Trial Office Urology
elsa.goossens@uzleuven.ac.be